Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › J-Pharma Co. Ltd. › 17638669
Last updated: October 25, 2026
Application No. 17/638,669

A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USED FOR A PATIENT HAVING SPECIFIC GENETIC MARKER

Final Rejection
Filed
Feb 25, 2022
Priority
Aug 30, 2019 — JP 2019-158681 +1 more
Examiner
GAUGER, PAUL RANDALL
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
J-Pharma Co. Ltd.
OA Round
3 (Final)
59%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
68%
With Interview

Interview Optional

— +8.3% interview lift. Interview lift (+8.3%) is below the 15.0% threshold. A written response is recommended.
Based on 27 resolved cases, 2023–2026

Examiner Intelligence

GAUGER, PAUL RANDALL View full profile →
Grants 59% of resolved cases
59%
Career Allowance Rate
16 granted / 27 resolved
-0.7% vs TC avg
Moderate +8% lift
Without
With
+8.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
16 currently pending
Career history
43
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
29.8%
-10.2% vs TC avg
§102
20.2%
-19.8% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 27 resolved cases

Prosecution Timeline

Show 2 earlier events
Jul 08, 2022
Response after Non-Final Action
Nov 03, 2025
Non-Final Rejection mailed
Jan 23, 2026
Response Filed
Jan 23, 2026
Response after Non-Final Action
Feb 24, 2026
Final Rejection mailed
Jun 24, 2026
Request for Continued Examination
Jun 25, 2026
Response after Non-Final Action
Sep 15, 2026
Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/314,015
Patent 12758542
METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMA
3y 5m to grant Granted Oct 13, 2026
18/004,009
Patent 12728119
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING 3-KETOACYL CoA THIOLASE INHIBITOR AND CARNITINE ACYLCARNITINE CARRIER INHIBITOR
3y 8m to grant Granted Sep 08, 2026
17/780,042
Patent 12655151
ION CHANNEL MODULATORS
4y 0m to grant Granted Jun 16, 2026
17/996,575
Patent 12629357
TREATMENT OF VIRAL INFECTIONS, OF ORGAN INJURY, AND OF RELATED CONDITIONS USING A HIF PROLYL HYDROXYLASE INHIBITOR OR A HIF-ALPHA STABILIZER
3y 7m to grant Granted May 19, 2026
18/036,735
Patent 12599592
THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION
2y 11m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
59%
Grant Probability
68%
With Interview (+8.3%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 27 resolved cases by this examiner. Grant probability derived from career allowance rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month